Effect of Enfortumab Vedotin Dose Adjustment on Efficacy in Metastatic Urothelial Carcinoma: A Retrospective Single-Center Experience 

Abstract

Anna Clennon,1 Megan Hinkley,1 Kristen Nymberg,1 Lauren Ledbetter,1 Demond Handley,2 Eric McLaughlin,2 Amir Mortazavi,3 Katharine A Collier3 1Department of Pharmacy, the James Cancer Hospital at the Ohio State University, Columbus, OH, USA; 2Department of Statistics, the Ohio State University, Columbus, OH, USA; 3Division of Medical Oncology, Department of Internal Medicine, College of Medicine, OH, USA State University, and the Comprehensive Cancer Center, Columbus, OH, USACorrespondence: Katharine A Collier, Division of Medical Oncology, Department of Internal Medicine, College of Medicine, OH, USA State University, and the Comprehensive Cancer Center, 400 W. 12th Ave, Wiseman Hall Rm 310, Columbus, OH, 43210, USA, Tel [phone], Fax [phone], Email [email protected]

Keywords

• urothelial carcinoma
• bladder cancer
• enfortumab
• dosing
• dose reduction